Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models
RNA-seq (gene expression) · mouse · 37 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 37 samples: 36 distinct titles, 1 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer modelsThe Journal of clinical investigation · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE328461_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1455483 and SRA study SRP693118. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 37 sample titles: 36 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9683940 1-spm-exphx-OPNn
- GSM9683941 1-spm-exphx-OPNp
- GSM9683942 1-spm-expnx-OPNp
- GSM9683943 1-spr-exphx-OPNn
- GSM9683944 1-spr-exphx-OPNp
- GSM9683945 1-spr-expnx-OPNn
- GSM9683946 1-spr-expnx-OPNp
- GSM9683947 1-spr-lavhx-OPNn
- GSM9683948 1-spr-lavhx-OPNp
- GSM9683949 1-spr-lavnx-OPNn
- GSM9683950 1-spr-lavnx-OPNp
- GSM9683951 2-spm-exphx-OPNn
- GSM9683952 2-spm-exphx-OPNp
- GSM9683953 2-spm-expnx-OPNn
- GSM9683954 2-spm-expnx-OPNp
- GSM9683955 2-spr-exphx-OPNn
- GSM9683956 2-spr-exphx-OPNp
- GSM9683957 2-spr-expnx-OPNn
- GSM9683958 2-spr-expnx-OPNp
- GSM9683959 2-spr-lavhx-OPNn
- GSM9683960 2-spr-lavhx-OPNp
- GSM9683961 2-spr-lavnx-OPNn
- GSM9683962 2-spr-lavnx-OPNp
- GSM9683963 3-spm-exphx-OPNn
- GSM9683964 3-spm-exphx-OPNp
- GSM9683965 3-spm-expnx-OPNn
- GSM9683966 3-spm-expnx-OPNp
- GSM9683967 3-spr-exphx-OPNn
- GSM9683968 3-spr-exphx-OPNp
- GSM9683969 3-spr-expnx-OPNn
- GSM9683970 3-spr-expnx-OPNp
- GSM9683971 3-spr-lavhx-OPNn
- GSM9683972 3-spr-lavhx-OPNp
- GSM9683973 3-spr-lavnx-OPNn
- GSM9683974 3-spr-lavnx-OPNp
- GSM9683975 naive-1
- GSM9683976 naive-2
- GSE241539 Osteopontin links acquired resistance to hypoxia-inducing antiangiogenics with refractoriness to anti-PD-L1 agents in breast cancer 13 samples shares anti-pd-l1, hypoxia-inducing, antiangiogenics, refractoriness, osteopontin, resistance, acquired
- GSE241527 Osteopontin links acquired resistance to hypoxia-inducing antiangiogenics with refractoriness to anti-PD-L1 agents in breast cancer [I] 7 samples shares anti-pd-l1, hypoxia-inducing, antiangiogenics, refractoriness, osteopontin, resistance, acquired
- GSE241538 Osteopontin links acquired resistance to hypoxia-inducing antiangiogenics with refractoriness to anti-PD-L1 agents in breast cancer [II] 6 samples shares anti-pd-l1, hypoxia-inducing, antiangiogenics, refractoriness, osteopontin, resistance, acquired
- GSE243273 Osteopontin links acquired resistance to hypoxia-inducing antiangiogenics with refractoriness to anti-PD-L1 agents in breast cancer [III] 5 samples shares anti-pd-l1, hypoxia-inducing, antiangiogenics, refractoriness, osteopontin, resistance, acquired
- GSE186037 Gene expression changes in mouse kidney cancer cells (RENCA) after anti-PD-L1 resistance 12 samples shares anti-pd-l1, resistance
- GSE186032 Gene expression changes in mouse breast tumor tissue (EMT6) after anti-PD-L1 resistance 7 samples shares anti-pd-l1, resistance
- GSE278396 Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1 [Bulk2] 15 samples shares anti-pd-l1
- GSE278013 Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1 [Bulk1] 14 samples shares anti-pd-l1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.